Sodium-Glucose Cotransporter 2 Inhibitors and Pulmonary Hypertension: A Systematic Review
- 4 April 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Cardiology in Review
Abstract
Pulmonary hypertension (PH) is a chronic disease characterized by elevated pulmonary arterial pressure, often leading to right ventricular failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are potential therapies for PH due to their cardiovascular effects. In this systematic review, we aim to assess the safety and efficacy of SGLT2 inhibitors in improving pulmonary hemodynamics and cardiac parameters in patients with PH. A systematic review search until November 2024 was conducted across 8 databases. Six studies involving 462 participants were included, comprising 3 randomized controlled trials, 2 observational studies, and 1 cohort study. SGLT2 inhibitors, particularly dapagliflozin and empagliflozin, significantly reduced pulmonary arterial pressure in most studies. Cardiac indices, such as left ventricular diastolic and systolic diameters, E/e’, and left ventricular ejection fraction, also improved. However, one randomized controlled trial reported no significant improvement in the hemodynamic outcomes. SGLT2 inhibitors are assumed to be promising in the management of PH through cardiac and hemodynamic improvements. Further research is needed to elucidate their efficacy and the underlying mechanisms.Keywords
This publication has 22 references indexed in Scilit:
- Recent Advances and Future Prospects of Treatment of Pulmonary HypertensionCurrent Problems in Cardiology, 2022
- SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure—further evidence for improved hemodynamics by continuous pressure monitoringClinical Research in Cardiology, 2021
- Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection FractionJACC, 2020
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine, 2020
- Effects of Dapagliflozin on Congestion Assessed by Remote Pulmonary Artery Pressure MonitoringESC Heart Failure, 2020
- The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertensionBiochemical and Biophysical Research Communications, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet, 2019
- Pulmonary Hypertension in Heart FailureJACC, 2017
- A global view of pulmonary hypertensionThe Lancet Respiratory Medicine, 2016